Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Payment, Tax Withholding, Share-Based Payment Arrangement

Payment, Tax Withholding, Share-Based Payment Arrangement at other companies

Biogen logo
BiogenBIIB
——
Globus Medical logo
Globus MedicalGMED
——
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's payment, tax withholding, share-based payment arrangement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's payment, tax withholding, share-based payment arrangement?
BioMarin Pharmaceuticals (BMRN) reported payment, tax withholding, share-based payment arrangement of $28.18M in Q1 2026.
How has BioMarin Pharmaceuticals's payment, tax withholding, share-based payment arrangement changed year-over-year?
BioMarin Pharmaceuticals's payment, tax withholding, share-based payment arrangement decreased by 27.3% year-over-year, from $38.78M to $28.18M.
What is the long-term trend for BioMarin Pharmaceuticals's payment, tax withholding, share-based payment arrangement?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's payment, tax withholding, share-based payment arrangement has grown at a 5.1% compound annual growth rate (CAGR), from $45.81M to $55.97M.